Narendranath Epperla1, Kami J Maddocks2, Mohammed Salhab3, Julio C Chavez4, Nishitha Reddy5, Reem Karmali6, Elvira Umyarova7, Veronika Bachanova8, Cristiana Costa9, Martha Glenn10, Oscar Calzada11, Ana C Xavier12, Zheng Zhou3, Nasheed M Hossain13, Francisco J Hernandez-Ilizaliturri14, Zeina Al-Mansour15, Stefan K Barta13, Saurabh Chhabra1, Frederick Lansigan16, Amitkumar Mehta12, Michael V Jaglal4, Andrew M Evens15, Christopher R Flowers11, Jonathon B Cohen11, Timothy S Fenske1, Mehdi Hamadani1, Luciano J Costa12. 1. Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Department of Hematology, Ohio State University, Columbus, Ohio. 3. Children's Medical Center, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts. 4. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida. 5. Department of Hematology/Oncology, Vanderbilt University, Nashville, Tennessee. 6. Department of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, Illinois. 7. Department of Medicine, Medical University of South Carolina, Charleston, South Carolina. 8. Division of Hematology, Oncology and Transplant, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 9. Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 10. University of Utah School of Medicine, Salt Lake City, Utah. 11. Winship Cancer Institute, Emory University, Atlanta, Georgia. 12. Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama. 13. Fox Chase Cancer Center, Philadelphia, Pennsylvania. 14. Department of Medicine, Roswell Park Cancer Center, Buffalo, New York. 15. Section of Hematology and Oncology, Department of Medicine, Tufts University Medical Center, Boston, Massachusetts. 16. Department of Hematology Oncology, Darmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Abstract
BACKGROUND: The impact of MYC proto-oncogene, basic helix-loop-helix (MYC) translocations (with or without additional rearrangements involving the B-cell lymphoma 2 [BCL2] or BCL6 genes) on the response to salvage therapy and survival in patients with diffuse large B-cell lymphoma (DLBCL) who experience primary treatment failure is not well defined. METHODS: This was a multicenter, retrospective study of the impact of MYC, BCL2, and BCL6 rearrangements in patients with DLBCL who failed to achieve complete remission or relapsed within 6 months after they completed upfront chemoimmunotherapy. RESULTS: The authors examined response to salvage therapy, receipt of hematopoietic cell transplantation (HCT), and survival outcomes in MYC-negative (n = 120), MYC-positive single hit (SH) (n = 20), and MYC-positive double hit/triple hit (DH/TH) (n = 35) cohorts. The overall response rate in these cohorts to first salvage therapy (51%, 50%, and 54%, respectively) and receipt of HCT (52%, 40%, and 43%, respectively) were comparable between the 3 cohorts. The 2-year overall survival rate was 29.9% in the MYC-negative cohort, 0% in the MYC-positive SH cohort, and 9.9% in the MYC-positive DH/TH cohort (P < .001), and no difference was observed between the SH and DH/TH cohorts (P = .8). The higher risk of death for patients with MYC-positive SH DLBCL (hazard ratio, 1.70; 95% confidence interval, 0.98-2.96; P = .06) and those with MYC-positive DH/TH DLBCL (hazard ratio, 2.22; 95% confidence interval, 1.41-3.50; P = .001) persisted after adjusting for covariates. For patients who underwent autologous HCT, the 2-year overall survival rate was 55.4% in the MYC-negative cohort, 0% in the MYC-positive SH cohort, and 19.4% in the MYC-positive DH/TH cohort (P < .001). All 4 MYC-positive patients who underwent allogeneic HCT relapsed in <4 months. CONCLUSIONS: Patients with MYC-positive DLBCL who experience primary treatment failure have response rates to similar to those achieved by salvage therapy compared with their MYC-negative counterparts, but their survival is dismal irrespective of additional "hits" and HCT, representing an unmet medical need. Cancer 2017;123:4411-8.
BACKGROUND: The impact of MYC proto-oncogene, basic helix-loop-helix (MYC) translocations (with or without additional rearrangements involving the B-cell lymphoma 2 [BCL2] or BCL6 genes) on the response to salvage therapy and survival in patients with diffuse large B-cell lymphoma (DLBCL) who experience primary treatment failure is not well defined. METHODS: This was a multicenter, retrospective study of the impact of MYC, BCL2, and BCL6 rearrangements in patients with DLBCL who failed to achieve complete remission or relapsed within 6 months after they completed upfront chemoimmunotherapy. RESULTS: The authors examined response to salvage therapy, receipt of hematopoietic cell transplantation (HCT), and survival outcomes in MYC-negative (n = 120), MYC-positive single hit (SH) (n = 20), and MYC-positive double hit/triple hit (DH/TH) (n = 35) cohorts. The overall response rate in these cohorts to first salvage therapy (51%, 50%, and 54%, respectively) and receipt of HCT (52%, 40%, and 43%, respectively) were comparable between the 3 cohorts. The 2-year overall survival rate was 29.9% in the MYC-negative cohort, 0% in the MYC-positive SH cohort, and 9.9% in the MYC-positive DH/TH cohort (P < .001), and no difference was observed between the SH and DH/TH cohorts (P = .8). The higher risk of death for patients with MYC-positive SH DLBCL (hazard ratio, 1.70; 95% confidence interval, 0.98-2.96; P = .06) and those with MYC-positive DH/TH DLBCL (hazard ratio, 2.22; 95% confidence interval, 1.41-3.50; P = .001) persisted after adjusting for covariates. For patients who underwent autologous HCT, the 2-year overall survival rate was 55.4% in the MYC-negative cohort, 0% in the MYC-positive SH cohort, and 19.4% in the MYC-positive DH/TH cohort (P < .001). All 4 MYC-positive patients who underwent allogeneic HCT relapsed in <4 months. CONCLUSIONS:Patients with MYC-positive DLBCL who experience primary treatment failure have response rates to similar to those achieved by salvage therapy compared with their MYC-negative counterparts, but their survival is dismal irrespective of additional "hits" and HCT, representing an unmet medical need. Cancer 2017;123:4411-8.
Authors: Rebecca L King; Ellen D McPhail; Reid G Meyer; George Vasmatzis; Kathryn Pearce; James B Smadbeck; Rhett P Ketterling; Stephanie A Smoley; Patricia T Greipp; Nicole L Hoppman; Jess F Peterson; Linda B Baughn Journal: Haematologica Date: 2018-12-06 Impact factor: 9.941
Authors: Nirav N Shah; Kwang W Ahn; Carlos Litovich; Yizeng He; Craig Sauter; Timothy S Fenske; Mehdi Hamadani Journal: Blood Date: 2021-03-11 Impact factor: 22.113
Authors: Madeleine R Berendsen; Wendy B C Stevens; Michiel van den Brand; J Han van Krieken; Blanca Scheijen Journal: Cancers (Basel) Date: 2020-11-28 Impact factor: 6.639